共 50 条
How Should We Treat HAP/VAP Caused by Carbapenemase-Producing Enterobacteriaceae?
被引:10
|作者:
Bassetti, Matteo
[1
,2
]
Peghin, Maddalena
[1
,2
]
Carnelutti, Alessia
[1
,2
]
Righi, Elda
[1
,2
]
机构:
[1] Univ Udine, Dept Med, Infect Dis Clin, Udine, Italy
[2] Santa Maria Misericordia Hosp, Udine, Italy
关键词:
hospital-acquired pneumonia;
ventilator-acquired pneumonia;
carbapenemase-producing Enterobacteriaceae;
antibiotic therapy;
multidrug-resistant gram negative;
VENTILATOR-ASSOCIATED PNEUMONIA;
CRITICALLY-ILL PATIENTS;
INTENSIVE-CARE-UNIT;
RESPIRATORY-TRACT INFECTIONS;
HOSPITAL-ACQUIRED PNEUMONIA;
KLEBSIELLA-PNEUMONIAE;
RISK-FACTORS;
RESISTANT ENTEROBACTERIACEAE;
COLISTIN METHANESULFONATE;
RETROSPECTIVE ANALYSIS;
D O I:
10.1055/s-0037-1602656
中图分类号:
R4 [临床医学];
学科分类号:
1002 ;
100602 ;
摘要:
Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) represent a common problem in hospital setting worldwide. Infections caused by carbapenem-resistant Enterobacteriaceae (CRE) are an emergent problem due to the lack of therapeutic options available, leading to significant increases in morbidity and mortality. CRE have frequently been reported both in HAP/VAP, but limited data regarding the optimal treatment strategy in this setting are available. This review focuses on the current epidemiology of CRE, with a specific focus on HAP/VAP. Moreover, we will suggest a possible strategy for the empiric and targeted treatment of HAP and VAP in which the involvement of CRE is suspected or is confirmed.
引用
收藏
页码:301 / 310
页数:10
相关论文